Skip to main content
Fig. 4 | BMC Medicine

Fig. 4

From: Serological study of CoronaVac vaccine and booster doses in Chile: immunogenicity and persistence of anti-SARS-CoV-2 spike antibodies

Fig. 4

Antibody titers of homologous and heterologous boosters of individuals previously vaccinated with two doses of CoronaVac. Participants from groups 3 and 4 received a complete CoronaVac vaccination scheme and booster after 6 to 8 months with BNT162b2, ChAdOx1, or CoronaVac vaccine. A Schema of participant’s immunizations. B Antibody titer comparison before and 30 days post booster immunization from BNT162b2 (19 individuals), ChAdOx1 (19 individuals), and CoronaVac (32 individuals) from study group 3. C Antibody titer comparison 100 days post booster immunization (median 122 days; IQR: 108–133 days) from BNT162b2 (27 individuals), ChAdOx1 (41 individuals), and CoronaVac (29 individuals) from study group 4. Each dot represents a serum sample. ****p < .0001, ***p < .001, **p < .01

Back to article page

BMC Medicine

ISSN: 1741-7015

Contact us